1. Forbes JM, Cooper ME. Mechanisms of diabetic complications.
Physiol Rev 93:137–188. 2013;
2. Shah MS, Brownlee M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes.
Circ Res 118:1808–1829. 2016;
3. Nathan DM. Diabetes: advances in diagnosis and treatment.
JAMA 314:1052–1062. 2015;
4. Fineberg D, Jandeleit-Dahm KA, Cooper ME. Diabetic nephropathy: diagnosis and treatment.
Nat Rev Endocrinol 9:713–723. 2013;
5. Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH. Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause?
Kidney Int 67:1684–1691. 2005;
6. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.
Circulation 108:2154–2169. 2003;
7. Kanwar YS, Sun L, Xie P, Liu FY, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy.
Annu Rev Pathol 6:395–423. 2011;
8. Kato M, Natarajan R. Diabetic nephropathy--emerging epigenetic mechanisms.
Nat Rev Nephrol 10:517–530. 2014;
9. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis.
Nat Rev Nephrol 12:325–338. 2016;
10. Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease.
J Clin Invest 124:2333–2340. 2014;
11. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome.
Nature 409:860–921. 2001;
12. Carninci P, Kasukawa T, Katayama S, et al. The transcriptional landscape of the mammalian genome.
Science 309:1559–1563. 2005;
14. Guttman M, Amit I, Garber M, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals.
Nature 458:223–227. 2009;
15. Cabili MN, Trapnell C, Goff L, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses.
Genes Dev 25:1915–1927. 2011;
16. Wapinski O, Chang HY. Long noncoding RNAs and human disease.
Trends Cell Biol 21:354–361. 2011;
17. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non-coding RNAs: regulators of disease.
J Pathol 220:126–139. 2010;
18. Moran VA, Perera RJ, Khalil AM. Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs.
Nucleic Acids Res 40:6391–6400. 2012;
19. Kato M, Wang M, Chen Z, et al. An endoplasmic reticulum stress-regulated lncRNA hosting a microRNA megacluster induces early features of diabetic nephropathy.
Nat Commun 7:12864.2016;
20. Long Y, Wang X, Youmans DT, Cech TR. How do lncRNAs regulate transcription?
Sci Adv 3:eaao2110.2017;
21. Bartel DP. Metazoan microRNAs.
Cell 173:20–51. 2018;
22. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?
Nat Rev Genet 9:102–114. 2008;
23. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing.
Nat Rev Mol Cell Biol 6:376–385. 2005;
24. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.
Cell 120:15–20. 2005;
25. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs.
Elife 4:e05005.2015;
26. Chi SW, Zang JB, Mele A, Darnell RB. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps.
Nature 460:479–486. 2009;
27. Helwak A, Kudla G, Dudnakova T, Tollervey D. Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding.
Cell 153:654–665. 2013;
28. Van Nostrand EL, Pratt GA, Shishkin AA, et al. Robust transcriptome-wide discovery of RNA-binding protein binding sites with enhanced CLIP (eCLIP).
Nat Methods 13:508–514. 2016;
29. Harvey SJ, Jarad G, Cunningham J, et al. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease.
J Am Soc Nephrol 19:2150–2158. 2008;
30. Ho J, Ng KH, Rosen S, Dostal A, Gregory RI, Kreidberg JA. Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury.
J Am Soc Nephrol 19:2069–2075. 2008;
31. Ho J, Pandey P, Schatton T, et al. The pro-apoptotic protein Bim is a microRNA target in kidney progenitors.
J Am Soc Nephrol 22:1053–1063. 2011;
32. Shi S, Yu L, Chiu C, et al. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis.
J Am Soc Nephrol 19:2159–2169. 2008;
33. Nagalakshmi VK, Ren Q, Pugh MM, et al. Dicer regulates the development of nephrogenic and ureteric compartments in the mammalian kidney.
Kidney Int 79:317–330. 2011;
34. Zhdanova O, Srivastava S, Di L, et al. The inducible deletion of drosha and microRNAs in mature podocytes results in a collapsing glomerulopathy.
Kidney Int 80:719–730. 2011;
35. Zhao Y, Ransom JF, Li A, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2.
Cell 129:303–317. 2007;
36. Chen JF, Murchison EP, Tang R, et al. Targeted deletion of dicer in the heart leads to dilated cardiomyopathy and heart failure.
Proc Natl Acad Sci U S A 105:2111–2116. 2008;
37. Sun Y, Koo S, White N, et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs.
Nucleic Acids Res 32:e188.2004;
38. Tian Z, Greene AS, Pietrusz JL, Matus IR, Liang M. MicroR-NA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis.
Genome Res 18:404–411. 2008;
39. Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of e-box repressors.
Proc Natl Acad Sci U S A 104:3432–3437. 2007;
40. Wang Q, Wang Y, Minto AW, et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy.
FASEB J 22:4126–4135. 2008;
41. Kato M, Putta S, Wang M, et al. Tgf-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN.
Nat Cell Biol 11:881–889. 2009;
42. Wang XX, Jiang T, Shen Y, et al. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model.
Diabetes 59:2916–2927. 2010;
43. Kato M, Wang L, Putta S, et al. Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-β-induced collagen expression in kidney cells.
J Biol Chem 285:34004–34015. 2010;
44. Park JT, Kato M, Yuan H, et al. FOG2 protein down-regulation by transforming growth factor-β1-induced microR-NA-200b/c leads to Akt kinase activation and glomerular mesangial hypertrophy related to diabetic nephropathy.
J Biol Chem 288:22469–22480. 2013;
45. Kato M, Arce L, Wang M, et al. A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells.
Kidney Int 80:358–368. 2011;
46. El-Osta A, Brasacchio D, Yao D, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia.
J Exp Med 205:2409–2417. 2008;
47. Kato M, Dang V, Wang M, et al. TGF-β induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy.
Sci Signal 6:ra43.2013;
48. Cooper ME, El-Osta A, Allen TJ, Watson AMD, Thomas MC, Jandeleit-Dahm KAM. Metabolic karma-the atherogenic legacy of diabetes: the 2017 Edwin Bierman Award Lecture.
Diabetes 67:785–790. 2018;
49. Kato M, Natarajan R. MicroRNA circuits in transforming growth factor-β actions and diabetic nephropathy.
Semin Nephrol 32:253–260. 2012;
50. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.
JAMA 290:2159–2167. 2003;
51. Kato M, Natarajan R. MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.
Ann N Y Acad Sci 1353:72–88. 2015;
52. Chung AC, Huang XR, Meng X, Lan HY. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis.
J Am Soc Nephrol 21:1317–1325. 2010;
53. Deshpande SD, Putta S, Wang M, et al. Transforming growth factor-β-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy.
Diabetes 62:3151–3162. 2013;
54. Mu J, Pang Q, Guo YH, et al. Functional implications of microRNA-215 in TGF-β1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1.
PLoS One 8:e58622.2013;
55. Wang B, Herman-Edelstein M, Koh P, et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta.
Diabetes 59:1794–1802. 2010;
56. Krupa A, Jenkins R, Luo DD, et al. Loss of microRNA-192 promotes fibrogenesis in diabetic nephropathy.
J Am Soc Nephrol 21:438–447. 2010;
57. Wang J, Gao Y, Ma M, et al. Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice.
Cell Biochem Biophys 67:537–546. 2013;
58. Zhong X, Chung AC, Chen HY, et al. MiR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes.
Diabetologia 56:663–674. 2013;
59. Chau BN, Xin C, Hartner J, et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways.
Sci Transl Med 4:121ra18.2012;
60. Kölling M, Kaucsar T, Schauerte C, et al. Therapeutic miR-21 silencing ameliorates diabetic kidney disease in mice.
Mol Ther 25:165–180. 2017;
61. Lai JY, Luo J, O’Connor C, et al. MicroRNA-21 in glomerular injury.
J Am Soc Nephrol 26:805–816. 2015;
62. Xu X, Kriegel AJ, Liu Y, et al. Delayed ischemic preconditioning contributes to renal protection by upregulation of miR-21.
Kidney Int 82:1167–1175. 2012;
63. Long J, Wang Y, Wang W, Chang BH, Danesh FR. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions.
J Biol Chem 285:23457–23465. 2010;
64. Soloaga A, Thomson S, Wiggin GR, et al. MSK2 and MSK1 mediate the mitogen–and stress–induced phosphorylation of histone H3 and HMG–14.
EMBO J 22:2788–2797. 2003;
65. Badal SS, Wang Y, Long J, et al. MiR-93 regulates MSK2-mediated chromatin remodelling in diabetic nephropathy.
Nat Commun 7:12076.2016;
66. Long J, Wang Y, Wang W, Chang BH, Danesh FR. MicroR-NA-29c is a signature microRNA under high glucose conditions that targets sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy.
J Biol Chem 286:11837–11848. 2011;
67. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis.
Proc Natl Acad Sci 105:13027–13032. 2008;
68. Wang B, Komers R, Carew R, et al. Suppression of microR-NA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis.
J Am Soc Nephrol 23:252–265. 2012;
69. Chen HY, Zhong X, Huang XR, et al. MicroRNA-29b inhibits diabetic nephropathy in db/db mice.
Mol Ther 22:842–853. 2014;
70. Qin W, Chung AC, Huang XR, et al. TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29.
J Am Soc Nephrol 22:1462–1474. 2011;
71. Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.
Diabetes 63:2120–2131. 2014;
72. Brennan EP, Nolan KA, Börgeson E, et al. Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1.
J Am Soc Nephrol 24:627–637. 2013;
73. Wang B, Jha JC, Hagiwara S, et al. Transforming growth factor-β1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b.
Kidney Int 85:352–361. 2014;
74. Park JT, Kato M, Lanting L, et al. Repression of let-7 by transforming growth factor-β1-induced Lin28 upregulates collagen expression in glomerular mesangial cells under diabetic conditions.
Am J Physiol Renal Physiol 307:F1390–F1403. 2014;
75. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28.
Science 320:97–100. 2008;
76. He F, Peng F, Xia X, et al. MiR-135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1.
Diabetologia 57:1726–1736. 2014;
77. Castro NE, Kato M, Park JT, Natarajan R. Transforming growth factor β1 (TGF-β1) enhances expression of profibrotic genes through a novel signaling cascade and microRNAs in renal mesangial cells.
J Biol Chem 289:29001–29013. 2014;
78. Wu J, Zheng C, Fan Y, et al. Downregulation of microRNA-30 facilitates podocyte injury and is prevented by glucocorticoids.
J Am Soc Nephrol 25:92–104. 2014;
79. Long J, Badal SS, Wang Y, et al. MicroRNA-22 is a master regulator of bone morphogenetic protein-7/6 homeostasis in the kidney.
J Biol Chem 288:36202–36214. 2013;
80. Li R, Chung AC, Dong Y, Yang W, Zhong X, Lan HY. The microRNA miR-433 promotes renal fibrosis by amplifying the TGF-β/Smad3-Azin1 pathway.
Kidney Int 84:1129–1144. 2013;
81. Dey N, Bera A, Das F, et al. High glucose enhances microRNA-26a to activate mTORC1 for mesangial cell hypertrophy and matrix protein expression.
Cell Signal 27:1276–1285. 2015;
82. Koga K, Yokoi H, Mori K, et al. MicroRNA-26a inhibits TGF-β-induced extracellular matrix protein expression in podocytes by targeting CTGF and is downregulated in diabetic nephropathy.
Diabetologia 58:2169–2180. 2015;
83. Zhao B, Li H, Liu J, et al. MicroRNA-23b targets Ras GT-Pase-activating protein SH3 domain-binding protein 2 to alleviate fibrosis and albuminuria in diabetic nephropathy.
J Am Soc Nephrol 27:2597–2608. 2016;
84. Bhatt K, Lanting LL, Jia Y, et al. Anti-inflammatory role of microRNA-146a in the pathogenesis of diabetic nephropathy.
J Am Soc Nephrol 27:2277–2288. 2016;
85. Lee HW, Khan SQ, Khaliqdina S, et al. Absence of miR-146a in podocytes increases risk of diabetic glomerulopathy via up-regulation of ErbB4 and Notch-1.
J Biol Chem 292:732–747. 2017;
86. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology 133:647–658. 2007;
87. Dey N, Ghosh-Choudhury N, Kasinath BS, Choudhury GG. TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion.
PLoS One 7:e42316.2012;
88. McClelland AD, Herman-Edelstein M, Komers R, et al. MiR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7.
Clin Sci (Lond) 129:1237–1249. 2015;
89. Zhang Z, Luo X, Ding S, et al. MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early diabetic nephropathy.
FEBS Lett 586:20–26. 2012;
90. Bera A, Das F, Ghosh-Choudhury N, Mariappan MM, Kasinath BS, Ghosh Choudhury G. Reciprocal regulation of miR-214 and PTEN by high glucose regulates renal glomerular mesangial and proximal tubular epithelial cell hypertrophy and matrix expansion.
Am J Physiol Cell Physiol 313:C430–C447. 2017;
91. Maity S, Bera A, Ghosh-Choudhury N, Das F, Kasinath BS, Choudhury GG. MicroRNA-181a downregulates deptor for TGFβ-induced glomerular mesangial cell hypertrophy and matrix protein expression.
Exp Cell Res 364:5–15. 2018;
92. Deshpande S, Abdollahi M, Wang M, et al. Reduced autophagy by a microRNA-mediated signaling cascade in diabetes-induced renal glomerular hypertrophy.
Sci Rep 8:6954.2018;
93. Bai X, Geng J, Li X, et al. Long noncoding RNA LINC01619 regulates MicroRNA-27a/forkhead box protein O1 and endoplasmic reticulum stress-mediated podocyte injury in diabetic nephropathy.
Antioxid Redox Signal 29:355–376. 2018;
94. Bischoff FC, Werner A, John D, et al. Identification and functional characterization of hypoxia-induced endoplasmic reticulum stress regulating lncRNA (HypERlnc) in pericytes.
Circ Res 121:368–375. 2017;
95. Alvarez ML, DiStefano JK. Functional characterization of the plasmacytoma variant translocation 1 gene (PVT1) in diabetic nephropathy.
PLoS One 6:e18671.2011;
96. Hanson RL, Craig DW, Millis MP, et al. Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study.
Diabetes 56:975–983. 2007;
97. Huppi K, Volfovsky N, Runfola T, et al. The identification of microRNAs in a genomically unstable region of human chromosome 8q24.
Mol Cancer Res 6:212–221. 2008;
98. Alvarez ML, Khosroheidari M, Eddy E, Kiefer J. Role of microRNA 1207-5P and its host gene, the long non-coding RNA Pvt1, as mediators of extracellular matrix accumulation in the kidney: implications for diabetic nephropathy.
PLoS One 8:e77468.2013;
99. Wang M, Wang S, Yao D, Yan Q, Lu W. A novel long non-coding RNA CYP4B1-PS1-001 regulates proliferation and fibrosis in diabetic nephropathy.
Mol Cell Endocrinol 426:136–145. 2016;
100. Hu M, Wang R, Li X, et al. LncRNA MALAT1 is dysregulated in diabetic nephropathy and involved in high glucose–induced podocyte injury via its interplay with β–catenin.
J Cell Mol Med 21:2732–2747. 2017;
101. Zhou Q, Chung AC, Huang XR, Dong Y, Yu X, Lan HY. Identification of novel long noncoding RNAs associated with TGF-β/Smad3-mediated renal inflammation and fibrosis by RNA sequencing.
Am J Pathol 184:409–417. 2014;
102. Tang W, Zhang D, Ma X. RNA-sequencing reveals genome-wide long non-coding RNAs profiling associated with early development of diabetic nephropathy.
Oncotarget 8:105832–105847. 2017;
103. Long J, Badal SS, Ye Z, et al. Long noncoding RNA Tug1 regulates mitochondrial bioenergetics in diabetic nephropathy.
J Clin Invest 126:4205–4218. 2016;
104. Sun SF, Tang PMK, Feng M, et al. Novel lncRNA Erbb4-IR promotes diabetic kidney injury in db/db mice by targeting miR-29b.
Diabetes 67:731–744. 2017;
105. Li A, Peng R, Sun Y, Liu H, Peng H, Zhang Z. LincRNA 1700020I14Rik alleviates cell proliferation and fibrosis in diabetic nephropathy via miR-34a-5p/Sirt1/HIF-1α signaling.
Cell Death Dis 9:461.2018;
106. Li X, Zeng L, Cao C, et al. Long noncoding RNA MALAT1 regulates renal tubular epithelial pyroptosis by modulated miR-23c targeting of ELAVL1 in diabetic nephropathy.
Exp Cell Res 350:327–335. 2017;
107. Lorenzen JM, Thum T. Long noncoding RNAs in kidney and cardiovascular diseases.
Nat Rev Nephrol 12:360–373. 2016;
108. Trionfini P, Benigni A, Remuzzi G. MicroRNAs in kidney physiology and disease.
Nat Rev Nephrol 11:23–33. 2015;
109. Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy.
Nat Rev Genet 17:272–283. 2016;
110. Babelova A, Avaniadi D, Jung O, et al. Role of Nox4 in murine models of kidney disease.
Free Radic Biol Med 53:842–853. 2012;
111. Zhu Y, Usui HK, Sharma K. Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment.
Semin Nephrol 27:153–160. 2007;
112. Kato M, Castro NE, Natarajan R. MicroRNAs: potential mediators and biomarkers of diabetic complications.
Free Radic Biol Med 64:85–94. 2013;
113. Fu Y, Zhang Y, Wang Z, et al. Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy.
Am J Nephrol 32:581–589. 2010;
114. Cheng TL, Wang Z, Liao Q, et al. MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex.
Dev Cell 28:547–560. 2014;
115. Jin Y, Ratnam K, Chuang PY, et al. A systems approach identifies HIPK2 as a key regulator of kidney fibrosis.
Nat Med 18:580–588. 2012;
116. Oh HJ, Kato M, Deshpande S, et al. Inhibition of the processing of miR-25 by HIPK2-phosphorylated-MeCP2 induces NOX4 in early diabetic nephropathy.
Sci Rep 6:38789.2016;
117. Feng B, Chen S, McArthur K, et al. MiR-146a-mediated extracellular matrix protein production in chronic diabetes complications.
Diabetes 60:2975–2984. 2011;
118. Muratsu-Ikeda S, Nangaku M, Ikeda Y, Tanaka T, Wada T, Inagi R. Downregulation of miR-205 modulates cell susceptibility to oxidative and endoplasmic reticulum stresses in renal tubular cells.
PLoS One 7:e41462.2012;
119. Kato M, Yuan H, Xu ZG, et al. Role of the Akt/FoxO3a pathway in TGF-β1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease.
J Am Soc Nephrol 17:3325–3335. 2006;
120. Wei J, Zhang Y, Luo Y, et al. Aldose reductase regulates miR-200a-3p/141-3pto coordinate Keap1–Nrf2, Tgfβ1/2, and Zeb1/2 signaling in renal mesangial cells and the renal cortex of diabetic mice.
Free Radic Biol Med 67:91–102. 2014;
121. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review.
Kidney Int 80:806–821. 2011;
122. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury.
Proc Natl Acad Sci U S A 106:4402–4407. 2009;
123. Szeto CC, Ching-Ha KB, Ka-Bik L, et al. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases.
Dis Markers 33:137–144. 2012;
124. Neal CS, Michael MZ, Pimlott LK, et al. Circulating microR-NA expression is reduced in chronic kidney disease.
Nephrol Dial Transplant 26:3794–3802. 2011;
125. Luk CC, Chow KM, Kwok JS, et al. Urinary biomarkers for the prediction of reversibility in acute-on-chronic renal failure.
Dis Markers 34:179–185. 2013;
126. Wang G, Kwan BC, Lai FM, Chow KM, Li PK, Szeto CC. Urinary sediment miRNA levels in adult nephrotic syndrome.
Clin Chim Acta 418:5–11. 2013;
127. Yang Y, Xiao L, Li J, Kanwar YS, Liu F, Sun L. Urine miR-NAs: potential biomarkers for monitoring progression of early stages of diabetic nephropathy.
Med Hypotheses 81:274–278. 2013;
128. Ichii O, Otsuka S, Sasaki N, Namiki Y, Hashimoto Y, Kon Y. Altered expression of microRNA miR-146a correlates with the development of chronic renal inflammation.
Kidney Int 81:280–292. 2012;
129. DiStefano JK, Taila M, Alvarez ML. Emerging roles for miRNAs in the development, diagnosis, and treatment of diabetic nephropathy.
Curr Diab Rep 13:582–591. 2013;
130. Cai X, Xia Z, Zhang C, et al. Serum microRNAs levels in primary focal segmental glomerulosclerosis.
Pediatr Nephrol 28:1797–1801. 2013;
131. Barutta F, Tricarico M, Corbelli A, et al. Urinary exosomal microRNAs in incipient diabetic nephropathy.
PLoS One 8:e73798.2013;
132. Argyropoulos C, Wang K, McClarty S, et al. Urinary microR-NA profiling in the nephropathy of type 1 diabetes.
PLoS One 8:e54662.2013;
133. Higuchi C, Nakatsuka A, Eguchi J, et al. Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes.
Metabolism 64:489–497. 2015;
134. Pezzolesi MG, Satake E, McDonnell KP, Major M, Smiles AM, Krolewski AS. Circulating TGF-β1-regulated miRNAs and the risk of rapid progression to ESRD in type 1 diabetes.
Diabetes 64:3285–3293. 2015;
135. Baker MA, Davis SJ, Liu P, et al. Tissue-specific microRNA expression patterns in four types of kidney disease.
J Am Soc Nephrol 28:2985–2992. 2017;
136. Jia Y, Guan M, Zheng Z, et al. MiRNAs in urine extracellular vesicles as predictors of early-stage diabetic nephropathy.
J Diabetes Res 2016:7932765.2016;
137. Cardenas-Gonzalez M, Srivastava A, Pavkovic M, et al. Identification, confirmation, and replication of novel urinary microRNA biomarkers in lupus nephritis and diabetic nephropathy.
Clin Chem 63:1515–1526. 2017;
138. Satake E, Pezzolesi MG, Md Dom ZI, Smiles AM, Niewczas MA, Krolewski AS. Circulating miRNA profiles associated with hyperglycemia in patients with type 1 diabetes.
Diabetes 67:1013–1023. 2018;
139. Goyal N, Kesharwani D, Datta M. Lncing non-coding RNAs with metabolism and diabetes: roles of lncRNAs.
Cell Mol Life Sci 75:1827–1837. 2018;
140. Declèves AE, Sharma K. New pharmacological treatments for improving renal outcomes in diabetes.
Nat Rev Nephrol 6:371–380. 2010;
141. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy.
Nat Rev Nephrol 6:319–330. 2010;
142. Krützfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomirs’.
Nature 438:685–689. 2005;
143. Putta S, Lanting L, Sun G, et al. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy.
J Am Soc Nephrol 23:458–469. 2012;
144. Lindow M, Kauppinen S. Discovering the first microRNA-targeted drug.
J Cell Biol 199:407–412. 2012;
145. Dey N, Das F, Mariappan MM, et al. MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes.
J Biol Chem 286:25586–25603. 2011;
146. Wahlestedt C. Targeting long non-coding RNA to therapeutically upregulate gene expression.
Nat Rev Drug Discov 12:433–446. 2013;
147. Stein CA, Hansen JB, Lai J, et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents.
Nucleic Acids Res 38:e3.2010;
148. Michalik KM, You X, Manavski Y, et al. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth.
Circ Res 114:1389–1397. 2014;
149. Lee JE, Bennett CF, Cooper TA. RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1.
Proc Natl Acad Sci 109:4221–4226. 2012;
150. Mahimainathan L, Das F, Venkatesan B, Choudhury GG. Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN.
Diabetes 55:2115–2125. 2006;
151. Wu D, Peng F, Zhang B, et al. PKC-β1 mediates glucose-induced Akt activation and TGF-β1 upregulation in mesangial cells.
J Am Soc Nephrol 20:554–566. 2009;
152. Xin X, Khan ZA, Chen S, Chakrabarti S. Glucose-induced Akt1 activation mediates fibronectin synthesis in endothelial cells.
Diabetologia 48:2428–2436. 2005;
153. Shemesh II, Rozen-Zvi B, Kalechman Y, Gafter U, Sredni B. AS101 prevents diabetic nephropathy progression and mesangial cell dysfunction: regulation of the AKT downstream pathway.
PLoS One 9:e114287.2014;
154. Sun L, Zhang D, Liu F, et al. Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192.
J Pathol 225:364–377. 2011;
155. Pan Y, Jia T, Zhang Y, et al. MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupusprone mice.
Int J Nanomedicine 7:5957–5967. 2012;
156. Woo JS, Kim VN. MeCP2 caught moonlighting as a suppressor of microRNA processing.
Dev Cell 28:477–478. 2014;
157. Bracaglia G, Conca B, Bergo A, et al. Methyl–CpG–binding protein 2 is phosphorylated by homeodomain–interacting protein kinase 2 and contributes to apoptosis.
EMBO Rep 10:1327–1333. 2009;
158. Liu R, Das B, Xiao W, et al. A novel inhibitor of homeodomain interacting protein kinase 2 mitigates kidney fibrosis through inhibition of the TGF-β1/Smad3 pathway.
J Am Soc Nephrol 28:2133–2143. 2017;
159. Roos M, Pradère U, Ngondo RP, et al. A small-molecule inhibitor of Lin28.
ACS Chem Biol 11:2773–2781. 2016;
160. Lightfoot HL, Miska EA, Balasubramanian S. Identification of small molecule inhibitors of the Lin28-mediated blockage of pre-let-7g processing.
Org Biomol Chem 14:10208–10216. 2016;
161. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9.
Science 346.2014.
162. Dominguez AA, Lim WA, Qi LS. Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation.
Nat Rev Mol Cell Biol 17:5–15. 2016;
163. Liao HK, Hatanaka F, Araoka T, et al. In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation.
Cell 171:1495–1507.e15. 2017;
164. Komor AC, Badran AH, Liu DR. CRISPR-based technologies for the manipulation of eukaryotic genomes.
Cell 168:20–36. 2017;
165. Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.
Nature 533:420–424. 2016;
166. Nishida K, Arazoe T, Yachie N, et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems.
Science 353:aaf8729.2016;
167. Kim YB, Komor AC, Levy JM, Packer MS, Zhao KT, Liu DR. Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions.
Nat Biotechnol 35:371–376. 2017;
168. Gaudelli NM, Komor AC, Rees HA, et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage.
Nature 551:464–471. 2017;
169. Mali P, Aach J, Stranges PB, et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering.
Nat Biotechnol 31:833–838. 2013;
170. Perez-Pinera P, Kocak DD, Vockley CM, et al. RNA-guided gene activation by CRISPR-Cas9–based transcription factors.
Nat Methods 10:973–976. 2013;
171. Gilbert LA, Horlbeck MA, Adamson B, et al. Genomescale CRISPR-mediated control of gene repression and activation.
Cell 159:647–661. 2014;
172. Kearns NA, Pham H, Tabak B, et al. Functional annotation of native enhancers with a Cas9-histone demethylase fusion.
Nat Methods 12:401–403. 2015;
173. Liu XS, Wu H, Ji X, et al. Editing DNA methylation in the mammalian genome.
Cell 167:233–247.e217. 2016;
174. Hilton IB, D’Ippolito AM, Vockley CM, et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol 33:510–517. 2015;
175. Verma N, Pan H, Doré LC, et al. TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells.
Nat Genet 50:83–95. 2018;
176. Morita S, Noguchi H, Horii T, et al. Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions.
Nat Biotechnol 34:1060–1065. 2016;